AtriCure, Inc. (ATRC)
AtriCure, Inc. (ATRC) from its SEC filings: 2025 revenue $534.5 million (+15% vs the year before), net margin -2%, free cash flow $48.3 million. Insider trades, recent filings and a price chart. Free.
| Exchange | Nasdaq |
| Industry | Surgical & Medical Instruments & Apparatus |
| Revenue (2025) | $534.5 million |
| Revenue growth | +15% |
| Net income | -$11.4 million |
| Net margin | -2.1% |
| Free cash flow | $48.3 million |
| Diluted EPS | $-0.24 |
| Latest quarter (Q2 2026 (calendar)) revenue vs a year earlier | +13% |
| Cash | $167.8 million |
| Long-term debt | $61.0 million |
| Share count, 1 year | +2% |
| Fundamentals check | Strong fundamentals |
Source: SEC EDGAR company filings (XBRL), updated 2026-10-24. Education only, not financial advice.